New combo aims to boost transplant success in stubborn leukemia
NCT ID NCT03247088
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 23 times
Summary
This study tests adding the targeted drug sorafenib to standard chemotherapy before a donor stem cell transplant in people with acute myeloid leukemia (AML) that has returned or not responded to treatment. The goal is to find the safest dose and see if it helps patients live longer without the cancer coming back. About 74 adults aged 18 to 70 with a matched donor are being enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.